Results 311 to 320 of about 373,608 (350)
Some of the next articles are maybe not open access.

Maspin is an angiogenesis inhibitor

Nature Medicine, 2000
Maspin, a unique member of the serpin family, is a secreted protein encoded by a class II tumor suppressor gene whose downregulation is associated with the development of breast and prostate cancers. Overexpression of maspin in breast tumor cells limits their growth and metastases in vivo.
M, Zhang, O, Volpert, Y H, Shi, N, Bouck
openaire   +2 more sources

Clinical translation of angiogenesis inhibitors

Nature Reviews Cancer, 2002
Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply. The successful translation of angiogenesis inhibitors to clinical application depends partly on the transfer of expertise from scientists who are familiar with the biology of angiogenesis to clinicians.
Robert, Kerbel, Judah, Folkman
openaire   +2 more sources

Thrombosis associated with angiogenesis inhibitors

Best Practice & Research Clinical Haematology, 2009
Recent advances in the understanding of the pathogenesis of cancer have led to the introduction of a variety of biological agents with novel mechanisms of action into clinical trials and even into clinical practice. In particular, tumour-associated neoangiogenesis has become a major target for this new class of antineoplastic agents.
Francesca, Elice   +3 more
openaire   +2 more sources

Investigational Angiogenesis Inhibitors

2010
Targeting angiogenesis is an evolving field of cancer research. Tumor angiogenesis is considered as an important step in the progression and metastasis of prostate cancer. Several pathways that converge toward promotion of growth, proliferation, and survival of prostate cancer cells have been targeted, including modulation of proangiogenic factors such
Jeanny B. Aragon-Ching, William Dahut
openaire   +1 more source

Identification of novel angiogenesis inhibitors

Bioorganic & Medicinal Chemistry Letters, 2005
Vascular endothelial growth factor (VEGF) is a key stimulant of angiogenesis, which is the process of generating new capillary blood vessels. Inhibition of the vascular endothelial growth factor receptor (VEGFR) kinase is known to result in blockage of angiogenesis.
Jayalakshmi, Sridhar   +5 more
openaire   +2 more sources

Angiogenesis and angiogenesis inhibitors in cancer.

Forum (Genoa, Italy), 1999
Angiogenesis, the development of a new blood supply, is an essential process of tumour growth and metastasis. Over the past few years, this has led to the consideration of the tumour vasculature as an optimal target for anti-cancer strategies. The process of angiogenesis consists of a series of interactive events: quiescent endothelial cells are ...
R, Giavazzi, G, Taraboletti
openaire   +1 more source

Angiogenesis inhibitors in lung cancer

Current Oncology Reports, 2002
Lung cancer is a major public health problem and the leading cause of cancer-related death worldwide. Its survival rates have changed little over the past 20 years. The best clinical benefit (ie, survival rates) with combination cytotoxic therapies in non-small-cell lung cancer (NSCLC) may have been reached.
Edward S, Kim, Roy S, Herbst
openaire   +2 more sources

[Tumor angiogenesis and tumor angiogenesis inhibitors].

Gan to kagaku ryoho. Cancer & chemotherapy, 2001
It is important to survey the molecular targets which are involved in tumor angiogenesis for the development of antiangiogenic agents as one of the cancer therapy. This article is meant to review the recent molecular targets of tumor angiogenesis and the molecular mechanism of antiangiogenic agents in human clinical trials.
M, Ono, M, Kuwano
openaire   +1 more source

Angiogenesis Inhibitors as Cancer Therapy

Hospital Practice, 1999
Angiogenesis inhibitors target a tumor's need to obtain nourishment from the host. In general, they are predicted to be chiefly cytostatic--that is, they stabilize tumors and perhaps prevent metastasis rather than being curative. Nevertheless, it remains conceivable that these agents may trigger tumor cell death.
openaire   +2 more sources

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Ca-A Cancer Journal for Clinicians, 2022
Sharon Elad, Noam Yarom, Yehuda Zadik
exaly  

Home - About - Disclaimer - Privacy